Greg Brown
Biography
Overview
Greg is an associate in the Firm's Capital Markets group in London.
His practice involves representing investment banks and issuers on a range of cross-border capital markets transactions, including US registered public offerings, Rule 144A/Reg S offerings and other public and private financings. Greg also counsels clients on ongoing disclosure obligations and compliance requirements under US securities laws.
Fullerton
Experience
Hiro Metaverse Acquisitions IPO, 2022
Represented Hiro Metaverse Acquisitions I S.A. on its £115 million initial public offering and listing on the London Stock Exchange.
Bidvest Bond Offering, 2021
Represented Bidvest Group (UK) Plc, a wholly owned subsidiary of The Bidvest Group Limited, on its offering of US$800 million 3.625% Senior Notes due 2026.
Reneo Pharmaceuticals IPO, 2021*
Represented Reneo Pharmaceuticals, Inc. on its $93.75 million initial public offering and listing on the Nasdaq Global Market.
Longboard Pharmaceuticals IPO, 2021*
Represented Longboard Pharmaceuticals, Inc. on its $80 million initial public offering and listing on the Nasdaq Global Market.
Artiva Biotherapeutics Series A, 2020*
Represented Artiva Biotherapeutics, Inc. on its $78 million series a preferred stock financing.
Turning Point Therapeutics Public Offering, 2020*
Represented Turning Point Therapeutics, Inc. on its $325 million underwritten public offering of its common stock.
Arena Pharmaceuticals Public Offering, 2020*
Represented Arena Pharmaceuticals, Inc. on its $316.3 million underwritten public offering of its common stock.
Turning Point Therapeutics IPO, 2019*
Represented Turning Point Therapeutics, Inc. on its $166.5 million initial public offering and listing on the Nasdaq Global Select Market.
*Matters worked on prior to joining White & Case.
